D.A Spandidos , V Zoumpourlis , A Kotsinas , H.R Maurer , P Patsilinacos
{"title":"顺式铂对人类免疫缺陷病毒长末端重复序列的转录激活作用","authors":"D.A Spandidos , V Zoumpourlis , A Kotsinas , H.R Maurer , P Patsilinacos","doi":"10.1016/0735-0651(90)90020-G","DOIUrl":null,"url":null,"abstract":"<div><p>We constructed a recombinant plasmid, pBHIV1 carrying the long terminal repeat (LTR) of the human immunodeficiency virus 1 (HIV-1), linked to the chloramphenicol acetyl transferase (CAT) gene plasmid. Plasmid pBHIV1 also contains the aminoglycoside phosphotransferase gene as a selectable marker. We introduced pBHIV1 in rat 208F fibroblasts and obtained stable geneticin resistant RFBHIV1-1 transfectant cells. A further control used was plasmid p202A, which carries the mutant T24 H-<em>ras</em>1 promoter linked to the promotorless <em>cat</em> gene. Plasmid p202A also carries the <em>aph</em> gene as a selectable marker and was transfected into 208F cells to obtain stable transfectant RF202A-1 cells. Both RFBHIV1-1 and RF202A-1 cells expressed CAT activity from the HIV LTR and T24 H-<em>ras</em>1 promoters. The response to <em>cis</em>-platin, a platin derivative and hexadecyl-phosphocholine was studied on the HIV LTR and H-<em>ras</em>1 regulated CAT activity in RFBHIV1-1 and RF202A-1 cells. It was found that at 5 × 10<sup>−5</sup> M concentrations <em>cis</em>-platin stimulates by 22-fold the expression of CAT from the HIV LTR, whereas only a 4-fold stimulation was observed on the T24 H-<em>ras</em>1 promoter. Our results suggest caution against therapy including this compound at cytotoxic concentrations in the treatment of AIDS patients.</p></div>","PeriodicalId":77714,"journal":{"name":"Gene analysis techniques","volume":"7 5","pages":"Pages 138-141"},"PeriodicalIF":0.0000,"publicationDate":"1990-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0735-0651(90)90020-G","citationCount":"8","resultStr":"{\"title\":\"Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by cis-platin\",\"authors\":\"D.A Spandidos , V Zoumpourlis , A Kotsinas , H.R Maurer , P Patsilinacos\",\"doi\":\"10.1016/0735-0651(90)90020-G\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We constructed a recombinant plasmid, pBHIV1 carrying the long terminal repeat (LTR) of the human immunodeficiency virus 1 (HIV-1), linked to the chloramphenicol acetyl transferase (CAT) gene plasmid. Plasmid pBHIV1 also contains the aminoglycoside phosphotransferase gene as a selectable marker. We introduced pBHIV1 in rat 208F fibroblasts and obtained stable geneticin resistant RFBHIV1-1 transfectant cells. A further control used was plasmid p202A, which carries the mutant T24 H-<em>ras</em>1 promoter linked to the promotorless <em>cat</em> gene. Plasmid p202A also carries the <em>aph</em> gene as a selectable marker and was transfected into 208F cells to obtain stable transfectant RF202A-1 cells. Both RFBHIV1-1 and RF202A-1 cells expressed CAT activity from the HIV LTR and T24 H-<em>ras</em>1 promoters. The response to <em>cis</em>-platin, a platin derivative and hexadecyl-phosphocholine was studied on the HIV LTR and H-<em>ras</em>1 regulated CAT activity in RFBHIV1-1 and RF202A-1 cells. It was found that at 5 × 10<sup>−5</sup> M concentrations <em>cis</em>-platin stimulates by 22-fold the expression of CAT from the HIV LTR, whereas only a 4-fold stimulation was observed on the T24 H-<em>ras</em>1 promoter. Our results suggest caution against therapy including this compound at cytotoxic concentrations in the treatment of AIDS patients.</p></div>\",\"PeriodicalId\":77714,\"journal\":{\"name\":\"Gene analysis techniques\",\"volume\":\"7 5\",\"pages\":\"Pages 138-141\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1990-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0735-0651(90)90020-G\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gene analysis techniques\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/073506519090020G\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gene analysis techniques","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/073506519090020G","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by cis-platin
We constructed a recombinant plasmid, pBHIV1 carrying the long terminal repeat (LTR) of the human immunodeficiency virus 1 (HIV-1), linked to the chloramphenicol acetyl transferase (CAT) gene plasmid. Plasmid pBHIV1 also contains the aminoglycoside phosphotransferase gene as a selectable marker. We introduced pBHIV1 in rat 208F fibroblasts and obtained stable geneticin resistant RFBHIV1-1 transfectant cells. A further control used was plasmid p202A, which carries the mutant T24 H-ras1 promoter linked to the promotorless cat gene. Plasmid p202A also carries the aph gene as a selectable marker and was transfected into 208F cells to obtain stable transfectant RF202A-1 cells. Both RFBHIV1-1 and RF202A-1 cells expressed CAT activity from the HIV LTR and T24 H-ras1 promoters. The response to cis-platin, a platin derivative and hexadecyl-phosphocholine was studied on the HIV LTR and H-ras1 regulated CAT activity in RFBHIV1-1 and RF202A-1 cells. It was found that at 5 × 10−5 M concentrations cis-platin stimulates by 22-fold the expression of CAT from the HIV LTR, whereas only a 4-fold stimulation was observed on the T24 H-ras1 promoter. Our results suggest caution against therapy including this compound at cytotoxic concentrations in the treatment of AIDS patients.